EUVIMEDEUVIMED entdecken
Open Access

Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice

Farhan M Qureshi, Julia K Panzer, Janika Põder, Thomas R Malek iD, Alejandro Caicedo iD

Diabetes · 2023

DOI: 10.2337/db22-0482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Farhan M Qureshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Prediabetic State. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low-dose IL-2 is a promising immunotherapy in clinical trials for treating type 1 diabetes. A new IL-2 analog, IL-2/CD25 fusion protein, has been shown to more efficiently delay or prevent diabetes in NOD mice by expanding the population of activated regulatory T cells. This therapy is intended for use before clinical diagnosis, in the early stages of type 1 diabetes progression. During this prediabetic period, there is a chronic decline in β-cell function that has long-term implications for disease pathogenesis. Yet, to date, the effects of IL-2/CD25 on β-cell function have not been evaluated. In this study, we treated prediabetic NOD mice with low-dose mouse IL-2/CD25 over 5 weeks and determined its impact on β-cell function. This treatment limited the progressive impairment of glucose tolerance and insulin secretion typical of the later stages of prediabetes. Intracellular Ca2+ responses to glucose in β-cells became more robust and synchronous, indicating that changing the local immune cell infiltrate with IL-2/CD25 preserved β-cell function even after treatment cessation. Our study thus provides mechanistic insight and serves as a steppingstone for future research using low-dose IL-2/CD25 immunotherapy in patients. Article Highlights Immunotherapies such as IL-2/CD25 are known to prevent or delay diabetes. However, their impact on individual β-cell function is not yet understood. Female NOD mice progress from stage 1 to 2 pre–type 1 diabetes between 12 and 17 weeks. Treatment with mouse IL-2 (mIL-2)/CD25 prevents this progression even after treatment cessation. Individual β-cell function (measured via intracellular Ca2+ responses to glucose) declines during the pathogenesis of type 1 diabetes. Treatment with mIL-2/CD25 therapy limits β-cell dysfunction, and function continues to improve after treatment cessation. Insulin secretion is improved with mIL-2/CD25 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Prediabetic StateFemaleAnimalsMiceMice, Inbred NODInterleukin-2CalciumT-Lymphocytes, RegulatoryGlucoseImmunotherapy

Substanzen

Interleukin-2CalciumGlucose

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
  • Department of Molecular, Cell and Developmental Biology, University of Miami Miller School of Medicine, Miami, FL.
  • Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL.
  • Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL.

ORCID-Profile: Thomas R Malek, Alejandro Caicedo

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS
  • NIEHS NIH HHS
  • National Institute of Environmental Health Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Leona M. and Harry B. Helmsley Charitable Trust
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Qureshi, F. M., Panzer, J. K., Põder, J., Malek, T. R., & Caicedo, A. (2023). Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice. Diabetes. https://doi.org/10.2337/db22-0482

Vancouver

Qureshi FM, Panzer JK, Põder J, Malek TR, Caicedo A. Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice. Diabetes. 2023. doi:10.2337/db22-0482

BibTeX
@article{Qureshi2023,
  author = {Qureshi, Farhan M and Panzer, Julia K and Põder, Janika and Malek, Thomas R and Caicedo, Alejandro},
  title = {Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice},
  journal = {Diabetes},
  year = {2023},
  doi = {10.2337/db22-0482}
}
Kostenlos starten →